Nautilus Biotechnology (NASDAQ:NAUT) Coverage Initiated at Leerink Partners

Investment analysts at Leerink Partners started coverage on shares of Nautilus Biotechnology (NASDAQ:NAUT) in a research note issued to investors on Wednesday, Briefing.com reports. The brokerage set an “outperform” rating and a $4.00 price target on the stock. Leerink Partners’ price objective indicates a potential upside of 304.04% from the company’s previous close.

Separately, Weiss Ratings downgraded shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.00.

Nautilus Biotechnology Stock Performance

NASDAQ NAUT traded up $0.06 on Wednesday, reaching $0.99. 137,734 shares of the stock traded hands, compared to its average volume of 524,630. The company has a fifty day moving average price of $1.24 and a 200-day moving average price of $2.19. The company has a market cap of $125.98 million, a price-to-earnings ratio of -2.22 and a beta of 0.87. Nautilus Biotechnology has a 12 month low of $0.68 and a 12 month high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings results on Tuesday, July 28th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.10 million.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NAUT. TD Waterhouse Canada Inc. increased its position in shares of Nautilus Biotechnology by 1,500.0% during the second quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock worth $29,000 after purchasing an additional 15,000 shares in the last quarter. Garde Capital Inc. acquired a new position in Nautilus Biotechnology during the 4th quarter valued at about $35,000. Hudson Bay Capital Management LP acquired a new position in Nautilus Biotechnology during the 4th quarter valued at about $37,000. Qube Research & Technologies Ltd purchased a new stake in Nautilus Biotechnology in the second quarter valued at about $45,000. Finally, Virtu Financial LLC raised its stake in Nautilus Biotechnology by 19.6% in the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock valued at $46,000 after buying an additional 3,849 shares during the last quarter. Institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.